Core Viewpoint - NEXGEL, Inc. has announced a definitive agreement for the issuance and sale of 413,044 shares of common stock at $2.30 per share, along with unregistered warrants for an additional 206,522 shares at an exercise price of $4.25, aimed at strengthening its balance sheet and providing working capital for anticipated growth in the second half of the year [1][2]. Group 1: Financial Details - The total number of shares being offered is 413,044 at a price of $2.30 each [1]. - Concurrently, NEXGEL will issue unregistered warrants to purchase up to 206,522 shares at an exercise price of $4.25, which are immediately exercisable for five years [1][2]. - The financing, combined with a recent $1 million non-dilutive advance from STADA, enhances the company's cash position [2]. Group 2: Regulatory Information - The shares are being offered under the company's shelf registration statement on Form S-3, which was declared effective by the SEC on June 7, 2023 [3]. - The unregistered warrants are offered under an exemption from registration requirements of the Securities Act [4]. Group 3: Company Overview - NEXGEL is a provider of healthcare, beauty, and OTC products, specializing in ultra-gentle, high-water-content hydrogels [6]. - The company has over two decades of experience in developing and manufacturing electron-beam, cross-linked hydrogels [6].

Company Overview - NEXGEL, Inc. is a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, based in Langhorne, Pennsylvania [1][3] - The company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades and offers brands such as SilverSeal, Hexagels, Turfguard, Kenkoderm, and Silly George [3] Partnership Expansion - NEXGEL announced an expansion of its partnership with STADA Arzneimittel AG, a European leader in consumer health, which includes the planned launch of digestive enzyme formulas and solutions targeting scars and stretch marks [1][2] - As part of the agreement, STADA will provide $1 million in non-dilutive capital to support NEXGEL's product launches and marketing efforts [2] Financial Performance of STADA - In the financial year 2024, STADA achieved group sales of €4,059 million and adjusted constant-currency earnings before interest, taxes, depreciation, and amortization (adj. cc EBITDA) of €886 million [2] - STADA operates globally, selling products in over 100 countries and employing 11,649 people as of December 31, 2024 [2]